Search
for
Sort by
Research 30 of 1000+
- Long-term symptom profiles after COVID-19<i>vs</i>other acute respiratory infections: a population-based observational study (COVIDENCE UK)
- Repetitive respiratory tract infection and trace elements zinc iron and cuprum in hair: A correlative study
- Symptoms Compatible With Long Coronavirus Disease (COVID) in Healthcare Workers With and Without Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection—Results of a Prospective Multicenter Cohort
- Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease‐19 (COVID‐19): A scoping review
- Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments
- Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management
- Diffused alopecia followed by severe acute respiratory syndrome coronavirus-2 infection
- ASSESSMENT OF THE FUNCTIONAL STATE OF THE RESPIRATORY SYSTEM AFTER RECOVERING FROM VIRAL INFECTION IN CHILDREN
- Immunologic and Autoimmune-Related Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- The Effects of Sex Hormones and some Respiratory Diseases on the Severity of Corona Virus Infection
- Late unexpected consequences of COVID‐19 infection in survivors of acute hypoxic respiratory failure
- Correlation between Androgenetic Alopecia and Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection in China
- BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
- Tofacitinib therapy for children with severe alopecia areata
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Response of alopecia areata of the beard to oral tofacitinib
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
- Baricitinib for the Treatment of Alopecia Areata
- Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
- Adverse effects of baricitinib in comparison to methotrexate in the treatment of severe alopecia areata